MX2009007850A - Tratamiento de incontinencia fecal. - Google Patents

Tratamiento de incontinencia fecal.

Info

Publication number
MX2009007850A
MX2009007850A MX2009007850A MX2009007850A MX2009007850A MX 2009007850 A MX2009007850 A MX 2009007850A MX 2009007850 A MX2009007850 A MX 2009007850A MX 2009007850 A MX2009007850 A MX 2009007850A MX 2009007850 A MX2009007850 A MX 2009007850A
Authority
MX
Mexico
Prior art keywords
groups
treatment
faecal incontinence
alkylidyne
cycloalkylene
Prior art date
Application number
MX2009007850A
Other languages
English (en)
Inventor
Hugues Bienayme
Jacques Ferte
Francisco Carlos Perez Martinez
Original Assignee
Urogene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene filed Critical Urogene
Publication of MX2009007850A publication Critical patent/MX2009007850A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe el uso de un compuesto que corresponde a la fórmula (I) (ver fórmula I) en la cual R representa hidrógeno o un grupo seleccionado de grupos alquilo, alquileno, alquilidino, cicloalquilo, cicloalquileno, cicloalquilidino y -CONH2, y los grupos -COR' y -COOR', en los cuales R' se selecciona de grupos alquilo, alquileno, alquilidino, cicloalquilo, cicloalquileno y cicloalquilidino, siendo posible que los grupos R y/o R' sean sustituidos y/o interrumpidos con funciones -O-, -COO-, -OCO-, -NHCO- y -CONH-, o una sal farmacéuticamente aceptable del compuesto, en la elaboración de un medicamento para usarse en el tratamiento de incontinencia fecal.
MX2009007850A 2007-01-26 2008-01-28 Tratamiento de incontinencia fecal. MX2009007850A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0700548A FR2911780A1 (fr) 2007-01-26 2007-01-26 Traitement de l'incontinence fecale.
US89871307P 2007-02-01 2007-02-01
PCT/IB2008/001296 WO2008090480A2 (en) 2007-01-26 2008-01-28 Treatment of faecal incontinence

Publications (1)

Publication Number Publication Date
MX2009007850A true MX2009007850A (es) 2009-08-24

Family

ID=38171270

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007850A MX2009007850A (es) 2007-01-26 2008-01-28 Tratamiento de incontinencia fecal.

Country Status (17)

Country Link
US (1) US20100063102A1 (es)
EP (1) EP2114530B1 (es)
JP (1) JP2010516753A (es)
KR (1) KR20090107551A (es)
CN (1) CN101610812A (es)
AT (1) ATE474576T1 (es)
AU (1) AU2008208627A1 (es)
BR (1) BRPI0807404A2 (es)
CA (1) CA2674636A1 (es)
DE (1) DE602008001877D1 (es)
FR (1) FR2911780A1 (es)
IL (1) IL199723A0 (es)
MA (1) MA31157B1 (es)
MX (1) MX2009007850A (es)
RU (1) RU2009124635A (es)
WO (1) WO2008090480A2 (es)
ZA (1) ZA200905208B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012247125B2 (en) * 2011-04-26 2017-03-09 Rdd Pharma Ltd. Oxymetazoline for the treatment of ano-rectal disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte

Also Published As

Publication number Publication date
EP2114530A2 (en) 2009-11-11
AU2008208627A1 (en) 2008-07-31
ATE474576T1 (de) 2010-08-15
BRPI0807404A2 (pt) 2014-05-20
IL199723A0 (en) 2010-04-15
RU2009124635A (ru) 2011-03-10
US20100063102A1 (en) 2010-03-11
CA2674636A1 (en) 2008-07-31
JP2010516753A (ja) 2010-05-20
WO2008090480A3 (en) 2008-11-06
DE602008001877D1 (de) 2010-09-02
WO2008090480A2 (en) 2008-07-31
EP2114530B1 (en) 2010-07-21
KR20090107551A (ko) 2009-10-13
MA31157B1 (fr) 2010-02-01
FR2911780A1 (fr) 2008-08-01
ZA200905208B (en) 2010-04-28
CN101610812A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
UA84460C2 (ru) Применение сульфонилкарбамидов для борьбы с нежелательным ростом растений в культурах бобовых
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
MX2011013016A (es) Derivados de aminopirrolidinona y usos de los mismos.
MX2010008921A (es) Derivados de oxazolidinona.
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
UA95766C2 (ru) Производные терфенила для лечения болезни альцгеймера
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
MX2009007850A (es) Tratamiento de incontinencia fecal.
MX2009006634A (es) Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer.
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
ATE391122T1 (de) 4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie
SE0402591D0 (sv) Novel use